Investment and acquisition is a key strategy for new medtech firms (and some that have been around a while). This means getting funding from outside parties and even selling whole operations to investors like venture capital funds.
But there’s been a decline in medtech investment. One explanation is the murkiness of regulatory risk – this risk is often opaque and hard to calculate. By “regulatory risk,” I mean the regulatory requirements and costs to market a medical device (more on this later)